Acute Lymphoblastic Leukemia
Conditions
Keywords
Ruxolitinib, Dasatinib, Dexamethasone, 14-272
Brief summary
The purpose of this study is to test the safety of a new combination of three oral drugs in Ph+ ALL. These drugs are dexamethasone, dasatinib, and ruxolitinib. All three drugs have been studied before in humans. This is a phase I study in which ruxolitinib dose will start low for the first patient together with dexamethasone plus dasatinib. If this dose does not cause a bad side effect, the ruxolitinib dose will slowly be made higher as new patients take part in the study. This will help the investigators find the right dose of ruxolitinib to give together with dexamethasone and dasatinib that will be used in future studies
Interventions
DRUGRuxolitinib
DRUGDasatinib
DRUGDexamethasone
Sponsors
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient able to give informed consent. * Patients \>/= 18 years with the following disease will be eligible * Newly diagnosed Ph+ ALL, previously untreated, except for the below allowances * Previously received HpyerCVAD cycle 1A+/- cycle 1B * Previously received Induction Phase 1 +/- Induction Phase II of BFM-modeled (Pediatric of Pediatric-Inspired) ALL regimen * Previously received other representative (modified from HyperCVAD, BFM, or AML-like) ALL induction course, including ABL TKI plus corticosteroid. * If the patient has received any of the above prior therapy, they may be enrolled, regardless of remission status. * Relapsed PH+ ALL, with no prior exposure to dasatinib and without known ABL kinase mutations predited to be resistant to dasatibin (e.g. L248R, L248V, Q252H, E255K, V299L, T315A, T315I, F317C, F317L, F317S, F317V) * Relapsed or refractory Ph-like ALL without prior exposure to dasatibin and with mutations or rearrangements of genes conferring sensitivity to dasatibin (ABL, CSF1R, PDGFRB) or ruxolitinib (CRLF2, JAK3, EPOR, TSLP) * Newly diagnosed or relapsed CML in lymphoid blast crisis * Confirmation of Philadelphia chromosome positivity by cytogenetics (karyotype/FISH) and/or molecular tests (BCR-ABL1 transcripts) * Acceptable end-organ function, except for documented exclusions for organ function compromise due to ALL itself * ECOG performance status ≤ 2 * Men and women of childbearing potential must be willing to practice an effective method of birth control during treatment and for at least 4 months following treatment on study
Exclusion criteria
* Ph-negative ALL * Patients with dominant leukemic clone bearing documented bcr-abl mutations enabling bcr-abl TKI resistance at diagnosis * Mature B-cell (Burkitt's) ALL * Serum creatinine \> 1.5x ULN and calculated creatinine clearance, based on a 24-hour urine collection, \< 30 mL/min--unless related to ALL/tumor lysis syndrome and able to be corrected * Direct Bilirubin \> 2x ULN; AST/ALT \> 10x ULN, unless related to ALL liver infiltration. * Pregnant women or women who are breast-feeding * Patients with HIV, Hepatitis B, or Hepatitis C * Pre-treatment QTcF \> 480 msecs * A "washout" period of at least 14 days from last previous cytotoxic chemotherapy will be required prior to starting treatment on this protocol. No "washout" period will be required for previous bcr-abl TKI therapy given with the aforementioned previous chemotherapy cycles. Hydroxyurea and corticosteroids may be given as bridge therapy up until 24 hours prior to initiating protocol treatment. * Active malignancy requiring treatment other than ALL within two years prior to start of treatment, with the exception of basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, localized prostate cancer, or DCIS or LCIS of the breast * Active, uncontrolled infection, any other concurrent disease, or medical condition that is deemed to interfere with the conduct of the study as judged by the investigator * Unable to tolerate anti-viral and anti- Pneumocystis jirovecii prophylaxis while on pre-phase and remission induction therapy * Unable to tolerate gastrointestinal prophylaxis therapy with sucralfate while on pre-phase and remission induction therapy. Or severe pre-existing GI disorder that requires PPI or H2 receptor antagonist therapy be uninterrupted
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical response | 2 years | is to be evaluated by using a combination of criteria. Molecular remissions will be defined by standard criteria for BCR-ABL1 and IGH qRT-PCR. Flow cytometric assessment of MRD will be defined by standard flow cytometry criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Molecular Remission (CMR) rate | 2 years | Molecular remission status will be defined by undetectable BCR-ABL1 transcripts and/or IGH clonal gene rearrangement in bone marrow aspirate (BMA) examination as determined by qRT-PCR in CLIA laboratory. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJae Park, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed